Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases Article Swipe
Masahiro Ayano
,
Kazuya Tsubouchi
,
Kunihiro Suzuki
,
Yasutaka Kimoto
,
Yojiro Arinobu
,
Koichi Akashi
,
Takahiko Horiuchi
,
Isamu Okamoto
,
Hiroaki Niiro
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1080/03009742.2024.2327159
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1080/03009742.2024.2327159
This study aimed to analyse whether initiating nintedanib treatment at a reduced dose could improve the treatment continuation rate while maintaining efficacy in patients with connective tissue disease (CTD)-associated interstitial lung disease. In total, 51 patients (age 61.6 ± 13.2 years; 38 women, 13 men) were retrospectively analysed. The primary endpoint was the cumulative discontinuation rate due to adverse events. Secondary endpoints included changes in drug dosage, efficacy evaluated based on annual changes in forced vital capacity (FVC), and safety assessed based on the frequency of adverse events. Eighteen patients who started treatment at the standard dose of 300 mg (standard dosage group) were compared with 33 patients who started treatment at a reduced dose (reduced dosage group). Systemic sclerosis was the most common CTD (n = 32), followed by idiopathic inflammatory myopathies and, rarely, rheumatoid arthritis. Both groups exhibited comparable cumulative discontinuation rates due to adverse events and similar frequencies of adverse events. No significant differences were observed in maintenance doses between the two groups; however, patients in the reduced dosage group had a lower cumulative dose for up to 52 weeks than those in the standard dosage group. No significant differences were observed in changes in FVC between the two groups. There was no evidence for a difference between the two groups in terms of discontinuation rates, efficacy, and safety. To provide further evidence, future studies using more precise dose-escalation protocols are warranted.
Related Topics
Concepts
Medicine
Discontinuation
Adverse effect
Internal medicine
Cumulative dose
Nintedanib
Vital capacity
Connective tissue disease
Interstitial lung disease
Clinical endpoint
Rheumatoid arthritis
Surgery
Clinical trial
Idiopathic pulmonary fibrosis
Lung
Disease
Diffusing capacity
Lung function
Autoimmune disease
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1080/03009742.2024.2327159
- OA Status
- green
- Cited By
- 2
- References
- 41
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4393409833
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4393409833Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1080/03009742.2024.2327159Digital Object Identifier
- Title
-
Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseasesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-04-02Full publication date if available
- Authors
-
Masahiro Ayano, Kazuya Tsubouchi, Kunihiro Suzuki, Yasutaka Kimoto, Yojiro Arinobu, Koichi Akashi, Takahiko Horiuchi, Isamu Okamoto, Hiroaki NiiroList of authors in order
- Landing page
-
https://doi.org/10.1080/03009742.2024.2327159Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://figshare.com/articles/journal_contribution/Comparing_the_safety_and_efficacy_of_nintedanib_starting_dose_in_patients_with_connective_tissue_disease-associated_interstitial_lung_diseases/25523982Direct OA link when available
- Concepts
-
Medicine, Discontinuation, Adverse effect, Internal medicine, Cumulative dose, Nintedanib, Vital capacity, Connective tissue disease, Interstitial lung disease, Clinical endpoint, Rheumatoid arthritis, Surgery, Clinical trial, Idiopathic pulmonary fibrosis, Lung, Disease, Diffusing capacity, Lung function, Autoimmune diseaseTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1, 2024: 1Per-year citation counts (last 5 years)
- References (count)
-
41Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4393409833 |
|---|---|
| doi | https://doi.org/10.1080/03009742.2024.2327159 |
| ids.doi | https://doi.org/10.6084/m9.figshare.25523982.v1 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38563202 |
| ids.openalex | https://openalex.org/W4393409833 |
| fwci | 1.72524628 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D005260 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | Female |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D008297 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Male |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008875 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Middle Aged |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D017563 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Lung Diseases, Interstitial |
| mesh[5].qualifier_ui | Q000008 |
| mesh[5].descriptor_ui | D007211 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | administration & dosage |
| mesh[5].descriptor_name | Indoles |
| mesh[6].qualifier_ui | Q000009 |
| mesh[6].descriptor_ui | D007211 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | adverse effects |
| mesh[6].descriptor_name | Indoles |
| mesh[7].qualifier_ui | Q000627 |
| mesh[7].descriptor_ui | D007211 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | therapeutic use |
| mesh[7].descriptor_name | Indoles |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D000368 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Aged |
| mesh[9].qualifier_ui | Q000188 |
| mesh[9].descriptor_ui | D003240 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | drug therapy |
| mesh[9].descriptor_name | Connective Tissue Diseases |
| mesh[10].qualifier_ui | Q000150 |
| mesh[10].descriptor_ui | D003240 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | complications |
| mesh[10].descriptor_name | Connective Tissue Diseases |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D012189 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Retrospective Studies |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D016896 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Treatment Outcome |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D014797 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Vital Capacity |
| mesh[14].qualifier_ui | Q000150 |
| mesh[14].descriptor_ui | D012595 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | complications |
| mesh[14].descriptor_name | Scleroderma, Systemic |
| mesh[15].qualifier_ui | Q000188 |
| mesh[15].descriptor_ui | D012595 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | drug therapy |
| mesh[15].descriptor_name | Scleroderma, Systemic |
| mesh[16].qualifier_ui | Q000008 |
| mesh[16].descriptor_ui | D047428 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | administration & dosage |
| mesh[16].descriptor_name | Protein Kinase Inhibitors |
| mesh[17].qualifier_ui | Q000009 |
| mesh[17].descriptor_ui | D047428 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | adverse effects |
| mesh[17].descriptor_name | Protein Kinase Inhibitors |
| mesh[18].qualifier_ui | Q000627 |
| mesh[18].descriptor_ui | D047428 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | therapeutic use |
| mesh[18].descriptor_name | Protein Kinase Inhibitors |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D004305 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Dose-Response Relationship, Drug |
| mesh[20].qualifier_ui | Q000188 |
| mesh[20].descriptor_ui | D001172 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | drug therapy |
| mesh[20].descriptor_name | Arthritis, Rheumatoid |
| mesh[21].qualifier_ui | Q000150 |
| mesh[21].descriptor_ui | D001172 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | complications |
| mesh[21].descriptor_name | Arthritis, Rheumatoid |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D006801 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Humans |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D005260 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Female |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D008297 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Male |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D008875 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Middle Aged |
| mesh[26].qualifier_ui | Q000188 |
| mesh[26].descriptor_ui | D017563 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | drug therapy |
| mesh[26].descriptor_name | Lung Diseases, Interstitial |
| mesh[27].qualifier_ui | Q000008 |
| mesh[27].descriptor_ui | D007211 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | administration & dosage |
| mesh[27].descriptor_name | Indoles |
| mesh[28].qualifier_ui | Q000009 |
| mesh[28].descriptor_ui | D007211 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | adverse effects |
| mesh[28].descriptor_name | Indoles |
| mesh[29].qualifier_ui | Q000627 |
| mesh[29].descriptor_ui | D007211 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | therapeutic use |
| mesh[29].descriptor_name | Indoles |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D000368 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Aged |
| mesh[31].qualifier_ui | Q000188 |
| mesh[31].descriptor_ui | D003240 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | drug therapy |
| mesh[31].descriptor_name | Connective Tissue Diseases |
| mesh[32].qualifier_ui | Q000150 |
| mesh[32].descriptor_ui | D003240 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | complications |
| mesh[32].descriptor_name | Connective Tissue Diseases |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D012189 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Retrospective Studies |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D016896 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Treatment Outcome |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D014797 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Vital Capacity |
| mesh[36].qualifier_ui | Q000150 |
| mesh[36].descriptor_ui | D012595 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | complications |
| mesh[36].descriptor_name | Scleroderma, Systemic |
| mesh[37].qualifier_ui | Q000188 |
| mesh[37].descriptor_ui | D012595 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | drug therapy |
| mesh[37].descriptor_name | Scleroderma, Systemic |
| mesh[38].qualifier_ui | Q000008 |
| mesh[38].descriptor_ui | D047428 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | administration & dosage |
| mesh[38].descriptor_name | Protein Kinase Inhibitors |
| mesh[39].qualifier_ui | Q000009 |
| mesh[39].descriptor_ui | D047428 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | adverse effects |
| mesh[39].descriptor_name | Protein Kinase Inhibitors |
| mesh[40].qualifier_ui | Q000627 |
| mesh[40].descriptor_ui | D047428 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | therapeutic use |
| mesh[40].descriptor_name | Protein Kinase Inhibitors |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D004305 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Dose-Response Relationship, Drug |
| mesh[42].qualifier_ui | Q000188 |
| mesh[42].descriptor_ui | D001172 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | drug therapy |
| mesh[42].descriptor_name | Arthritis, Rheumatoid |
| mesh[43].qualifier_ui | Q000150 |
| mesh[43].descriptor_ui | D001172 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | complications |
| mesh[43].descriptor_name | Arthritis, Rheumatoid |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D006801 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Humans |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D005260 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Female |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D008297 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Male |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D008875 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Middle Aged |
| mesh[48].qualifier_ui | Q000188 |
| mesh[48].descriptor_ui | D017563 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | drug therapy |
| mesh[48].descriptor_name | Lung Diseases, Interstitial |
| mesh[49].qualifier_ui | Q000008 |
| mesh[49].descriptor_ui | D007211 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | administration & dosage |
| mesh[49].descriptor_name | Indoles |
| type | article |
| title | Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases |
| biblio.issue | 4 |
| biblio.volume | 53 |
| biblio.last_page | 262 |
| biblio.first_page | 255 |
| topics[0].id | https://openalex.org/T10870 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis |
| topics[1].id | https://openalex.org/T11330 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9998999834060669 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2734 |
| topics[1].subfield.display_name | Pathology and Forensic Medicine |
| topics[1].display_name | Systemic Sclerosis and Related Diseases |
| topics[2].id | https://openalex.org/T11724 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9979000091552734 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2713 |
| topics[2].subfield.display_name | Epidemiology |
| topics[2].display_name | Inflammatory Myopathies and Dermatomyositis |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9507887363433838 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2778715236 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8041433691978455 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q55622662 |
| concepts[1].display_name | Discontinuation |
| concepts[2].id | https://openalex.org/C197934379 |
| concepts[2].level | 2 |
| concepts[2].score | 0.8035228252410889 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[2].display_name | Adverse effect |
| concepts[3].id | https://openalex.org/C126322002 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6437239646911621 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[3].display_name | Internal medicine |
| concepts[4].id | https://openalex.org/C151032500 |
| concepts[4].level | 2 |
| concepts[4].score | 0.6381332874298096 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q5194182 |
| concepts[4].display_name | Cumulative dose |
| concepts[5].id | https://openalex.org/C2780171596 |
| concepts[5].level | 4 |
| concepts[5].score | 0.6252894997596741 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q15149723 |
| concepts[5].display_name | Nintedanib |
| concepts[6].id | https://openalex.org/C55520419 |
| concepts[6].level | 5 |
| concepts[6].score | 0.5691565871238708 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q660995 |
| concepts[6].display_name | Vital capacity |
| concepts[7].id | https://openalex.org/C2776670291 |
| concepts[7].level | 4 |
| concepts[7].score | 0.5674453377723694 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1779300 |
| concepts[7].display_name | Connective tissue disease |
| concepts[8].id | https://openalex.org/C2777543607 |
| concepts[8].level | 3 |
| concepts[8].score | 0.5153912305831909 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1153419 |
| concepts[8].display_name | Interstitial lung disease |
| concepts[9].id | https://openalex.org/C203092338 |
| concepts[9].level | 3 |
| concepts[9].score | 0.5078478455543518 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1340863 |
| concepts[9].display_name | Clinical endpoint |
| concepts[10].id | https://openalex.org/C2777575956 |
| concepts[10].level | 2 |
| concepts[10].score | 0.48685139417648315 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q187255 |
| concepts[10].display_name | Rheumatoid arthritis |
| concepts[11].id | https://openalex.org/C141071460 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3711063861846924 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q40821 |
| concepts[11].display_name | Surgery |
| concepts[12].id | https://openalex.org/C535046627 |
| concepts[12].level | 2 |
| concepts[12].score | 0.2999858260154724 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[12].display_name | Clinical trial |
| concepts[13].id | https://openalex.org/C2778341716 |
| concepts[13].level | 3 |
| concepts[13].score | 0.2725105583667755 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q2290446 |
| concepts[13].display_name | Idiopathic pulmonary fibrosis |
| concepts[14].id | https://openalex.org/C2777714996 |
| concepts[14].level | 2 |
| concepts[14].score | 0.2650826573371887 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7886 |
| concepts[14].display_name | Lung |
| concepts[15].id | https://openalex.org/C2779134260 |
| concepts[15].level | 2 |
| concepts[15].score | 0.25269728899002075 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[15].display_name | Disease |
| concepts[16].id | https://openalex.org/C165637977 |
| concepts[16].level | 4 |
| concepts[16].score | 0.11850196123123169 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q11067835 |
| concepts[16].display_name | Diffusing capacity |
| concepts[17].id | https://openalex.org/C3018587741 |
| concepts[17].level | 3 |
| concepts[17].score | 0.08860701322555542 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7886 |
| concepts[17].display_name | Lung function |
| concepts[18].id | https://openalex.org/C2779075594 |
| concepts[18].level | 3 |
| concepts[18].score | 0.07790464162826538 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q8084905 |
| concepts[18].display_name | Autoimmune disease |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9507887363433838 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/discontinuation |
| keywords[1].score | 0.8041433691978455 |
| keywords[1].display_name | Discontinuation |
| keywords[2].id | https://openalex.org/keywords/adverse-effect |
| keywords[2].score | 0.8035228252410889 |
| keywords[2].display_name | Adverse effect |
| keywords[3].id | https://openalex.org/keywords/internal-medicine |
| keywords[3].score | 0.6437239646911621 |
| keywords[3].display_name | Internal medicine |
| keywords[4].id | https://openalex.org/keywords/cumulative-dose |
| keywords[4].score | 0.6381332874298096 |
| keywords[4].display_name | Cumulative dose |
| keywords[5].id | https://openalex.org/keywords/nintedanib |
| keywords[5].score | 0.6252894997596741 |
| keywords[5].display_name | Nintedanib |
| keywords[6].id | https://openalex.org/keywords/vital-capacity |
| keywords[6].score | 0.5691565871238708 |
| keywords[6].display_name | Vital capacity |
| keywords[7].id | https://openalex.org/keywords/connective-tissue-disease |
| keywords[7].score | 0.5674453377723694 |
| keywords[7].display_name | Connective tissue disease |
| keywords[8].id | https://openalex.org/keywords/interstitial-lung-disease |
| keywords[8].score | 0.5153912305831909 |
| keywords[8].display_name | Interstitial lung disease |
| keywords[9].id | https://openalex.org/keywords/clinical-endpoint |
| keywords[9].score | 0.5078478455543518 |
| keywords[9].display_name | Clinical endpoint |
| keywords[10].id | https://openalex.org/keywords/rheumatoid-arthritis |
| keywords[10].score | 0.48685139417648315 |
| keywords[10].display_name | Rheumatoid arthritis |
| keywords[11].id | https://openalex.org/keywords/surgery |
| keywords[11].score | 0.3711063861846924 |
| keywords[11].display_name | Surgery |
| keywords[12].id | https://openalex.org/keywords/clinical-trial |
| keywords[12].score | 0.2999858260154724 |
| keywords[12].display_name | Clinical trial |
| keywords[13].id | https://openalex.org/keywords/idiopathic-pulmonary-fibrosis |
| keywords[13].score | 0.2725105583667755 |
| keywords[13].display_name | Idiopathic pulmonary fibrosis |
| keywords[14].id | https://openalex.org/keywords/lung |
| keywords[14].score | 0.2650826573371887 |
| keywords[14].display_name | Lung |
| keywords[15].id | https://openalex.org/keywords/disease |
| keywords[15].score | 0.25269728899002075 |
| keywords[15].display_name | Disease |
| keywords[16].id | https://openalex.org/keywords/diffusing-capacity |
| keywords[16].score | 0.11850196123123169 |
| keywords[16].display_name | Diffusing capacity |
| keywords[17].id | https://openalex.org/keywords/lung-function |
| keywords[17].score | 0.08860701322555542 |
| keywords[17].display_name | Lung function |
| keywords[18].id | https://openalex.org/keywords/autoimmune-disease |
| keywords[18].score | 0.07790464162826538 |
| keywords[18].display_name | Autoimmune disease |
| language | en |
| locations[0].id | doi:10.1080/03009742.2024.2327159 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S42124886 |
| locations[0].source.issn | 0300-9742, 1502-7732 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0300-9742 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Scandinavian Journal of Rheumatology |
| locations[0].source.host_organization | https://openalex.org/P4310320547 |
| locations[0].source.host_organization_name | Taylor & Francis |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320547 |
| locations[0].source.host_organization_lineage_names | Taylor & Francis |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Scandinavian Journal of Rheumatology |
| locations[0].landing_page_url | https://doi.org/10.1080/03009742.2024.2327159 |
| locations[1].id | pmid:38563202 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Scandinavian journal of rheumatology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38563202 |
| locations[2].id | pmh:oai:figshare.com:article/25523982 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400572 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | OPAL (Open@LaTrobe) (La Trobe University) |
| locations[2].source.host_organization | https://openalex.org/I196829312 |
| locations[2].source.host_organization_name | La Trobe University |
| locations[2].source.host_organization_lineage | https://openalex.org/I196829312 |
| locations[2].license | cc-by |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://figshare.com/articles/journal_contribution/Comparing_the_safety_and_efficacy_of_nintedanib_starting_dose_in_patients_with_connective_tissue_disease-associated_interstitial_lung_diseases/25523982 |
| locations[3].id | doi:10.6084/m9.figshare.25523982.v1 |
| locations[3].is_oa | True |
| locations[3].source | |
| locations[3].license | cc-by |
| locations[3].pdf_url | |
| locations[3].version | |
| locations[3].raw_type | article-journal |
| locations[3].license_id | https://openalex.org/licenses/cc-by |
| locations[3].is_accepted | False |
| locations[3].is_published | |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://doi.org/10.6084/m9.figshare.25523982.v1 |
| indexed_in | crossref, datacite, pubmed |
| authorships[0].author.id | https://openalex.org/A5013618903 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-2954-9676 |
| authorships[0].author.display_name | Masahiro Ayano |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I135598925 |
| authorships[0].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Kyushu University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | M Ayano |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[1].author.id | https://openalex.org/A5032950976 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-0145-8745 |
| authorships[1].author.display_name | Kazuya Tsubouchi |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I135598925 |
| authorships[1].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Kyushu University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | K Tsubouchi |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[2].author.id | https://openalex.org/A5100650775 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-2565-5807 |
| authorships[2].author.display_name | Kunihiro Suzuki |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I135598925 |
| authorships[2].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Kyushu University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | K Suzuki |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[3].author.id | https://openalex.org/A5077117032 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-0158-2917 |
| authorships[3].author.display_name | Yasutaka Kimoto |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I135598925 |
| authorships[3].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Kyushu University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Y Kimoto |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[4].author.id | https://openalex.org/A5064060072 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-3485-2378 |
| authorships[4].author.display_name | Yojiro Arinobu |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I135598925 |
| authorships[4].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Kyushu University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Y Arinobu |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[5].author.id | https://openalex.org/A5102870989 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-7763-5723 |
| authorships[5].author.display_name | Koichi Akashi |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I135598925 |
| authorships[5].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Kyushu University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | K Akashi |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[6].author.id | https://openalex.org/A5030740263 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-1770-1087 |
| authorships[6].author.display_name | Takahiko Horiuchi |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210151129 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I4210151129 |
| authorships[6].institutions[0].ror | https://ror.org/04qdbg778 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I135598925, https://openalex.org/I4210151129 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Kyushu University Beppu Hospital |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | T Horiuchi |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan |
| authorships[7].author.id | https://openalex.org/A5072724155 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-7587-6096 |
| authorships[7].author.display_name | Isamu Okamoto |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I135598925 |
| authorships[7].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Kyushu University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | I Okamoto |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[8].author.id | https://openalex.org/A5077232803 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-0914-9066 |
| authorships[8].author.display_name | Hiroaki Niiro |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I135598925 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Medical Education, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I135598925 |
| authorships[8].institutions[0].ror | https://ror.org/00p4k0j84 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I135598925 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Kyushu University |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | H Niiro |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Medical Education, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://figshare.com/articles/journal_contribution/Comparing_the_safety_and_efficacy_of_nintedanib_starting_dose_in_patients_with_connective_tissue_disease-associated_interstitial_lung_diseases/25523982 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10870 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis |
| related_works | https://openalex.org/W3082109398, https://openalex.org/W2811389906, https://openalex.org/W4322504887, https://openalex.org/W4283576580, https://openalex.org/W3014847802, https://openalex.org/W3033248631, https://openalex.org/W3185059932, https://openalex.org/W3202744586, https://openalex.org/W4240796473, https://openalex.org/W3166857906 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | pmh:oai:figshare.com:article/25523982 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306400572 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | OPAL (Open@LaTrobe) (La Trobe University) |
| best_oa_location.source.host_organization | https://openalex.org/I196829312 |
| best_oa_location.source.host_organization_name | La Trobe University |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I196829312 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://figshare.com/articles/journal_contribution/Comparing_the_safety_and_efficacy_of_nintedanib_starting_dose_in_patients_with_connective_tissue_disease-associated_interstitial_lung_diseases/25523982 |
| primary_location.id | doi:10.1080/03009742.2024.2327159 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S42124886 |
| primary_location.source.issn | 0300-9742, 1502-7732 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0300-9742 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Scandinavian Journal of Rheumatology |
| primary_location.source.host_organization | https://openalex.org/P4310320547 |
| primary_location.source.host_organization_name | Taylor & Francis |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320547 |
| primary_location.source.host_organization_lineage_names | Taylor & Francis |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Scandinavian Journal of Rheumatology |
| primary_location.landing_page_url | https://doi.org/10.1080/03009742.2024.2327159 |
| publication_date | 2024-04-02 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W3203552048, https://openalex.org/W3172758942, https://openalex.org/W4383620394, https://openalex.org/W3003931585, https://openalex.org/W3009957091, https://openalex.org/W3120511139, https://openalex.org/W4289223617, https://openalex.org/W2169645723, https://openalex.org/W2070980574, https://openalex.org/W1970668845, https://openalex.org/W3206370684, https://openalex.org/W4311487211, https://openalex.org/W2804065941, https://openalex.org/W4380370756, https://openalex.org/W4210385475, https://openalex.org/W2945521814, https://openalex.org/W4291993875, https://openalex.org/W2974960379, https://openalex.org/W3010166382, https://openalex.org/W4213418035, https://openalex.org/W3047341706, https://openalex.org/W4223500234, https://openalex.org/W4317838235, https://openalex.org/W2913878462, https://openalex.org/W4385513942, https://openalex.org/W4382242825, https://openalex.org/W2152974152, https://openalex.org/W2508060872, https://openalex.org/W2765099479, https://openalex.org/W3022289262, https://openalex.org/W4210817412, https://openalex.org/W2965565685, https://openalex.org/W2997068357, https://openalex.org/W2104669609, https://openalex.org/W1857071204, https://openalex.org/W2105632276, https://openalex.org/W4382938072, https://openalex.org/W3012935775, https://openalex.org/W3033248631, https://openalex.org/W2904388381, https://openalex.org/W4225755260 |
| referenced_works_count | 41 |
| abstract_inverted_index.= | 126 |
| abstract_inverted_index.a | 10, 112, 174, 208 |
| abstract_inverted_index.(n | 125 |
| abstract_inverted_index.13 | 43 |
| abstract_inverted_index.33 | 106 |
| abstract_inverted_index.38 | 41 |
| abstract_inverted_index.51 | 34 |
| abstract_inverted_index.52 | 181 |
| abstract_inverted_index.In | 32 |
| abstract_inverted_index.No | 154, 190 |
| abstract_inverted_index.To | 222 |
| abstract_inverted_index.at | 9, 93, 111 |
| abstract_inverted_index.by | 129 |
| abstract_inverted_index.in | 22, 64, 73, 159, 168, 185, 195, 197, 214 |
| abstract_inverted_index.mg | 99 |
| abstract_inverted_index.no | 205 |
| abstract_inverted_index.of | 85, 97, 151, 216 |
| abstract_inverted_index.on | 70, 82 |
| abstract_inverted_index.to | 3, 57, 145, 180 |
| abstract_inverted_index.up | 179 |
| abstract_inverted_index.± | 38 |
| abstract_inverted_index.300 | 98 |
| abstract_inverted_index.CTD | 124 |
| abstract_inverted_index.FVC | 198 |
| abstract_inverted_index.The | 48 |
| abstract_inverted_index.and | 78, 148, 220 |
| abstract_inverted_index.are | 233 |
| abstract_inverted_index.due | 56, 144 |
| abstract_inverted_index.for | 178, 207 |
| abstract_inverted_index.had | 173 |
| abstract_inverted_index.the | 15, 52, 83, 94, 121, 163, 169, 186, 200, 211 |
| abstract_inverted_index.two | 164, 201, 212 |
| abstract_inverted_index.was | 51, 120, 204 |
| abstract_inverted_index.who | 90, 108 |
| abstract_inverted_index.(age | 36 |
| abstract_inverted_index.13.2 | 39 |
| abstract_inverted_index.32), | 127 |
| abstract_inverted_index.61.6 | 37 |
| abstract_inverted_index.Both | 137 |
| abstract_inverted_index.This | 0 |
| abstract_inverted_index.and, | 133 |
| abstract_inverted_index.dose | 12, 96, 114, 177 |
| abstract_inverted_index.drug | 65 |
| abstract_inverted_index.lung | 30 |
| abstract_inverted_index.men) | 44 |
| abstract_inverted_index.more | 229 |
| abstract_inverted_index.most | 122 |
| abstract_inverted_index.rate | 18, 55 |
| abstract_inverted_index.than | 183 |
| abstract_inverted_index.were | 45, 103, 157, 193 |
| abstract_inverted_index.with | 24, 105 |
| abstract_inverted_index.There | 203 |
| abstract_inverted_index.aimed | 2 |
| abstract_inverted_index.based | 69, 81 |
| abstract_inverted_index.could | 13 |
| abstract_inverted_index.doses | 161 |
| abstract_inverted_index.group | 172 |
| abstract_inverted_index.lower | 175 |
| abstract_inverted_index.rates | 143 |
| abstract_inverted_index.study | 1 |
| abstract_inverted_index.terms | 215 |
| abstract_inverted_index.those | 184 |
| abstract_inverted_index.using | 228 |
| abstract_inverted_index.vital | 75 |
| abstract_inverted_index.weeks | 182 |
| abstract_inverted_index.while | 19 |
| abstract_inverted_index.(FVC), | 77 |
| abstract_inverted_index.annual | 71 |
| abstract_inverted_index.common | 123 |
| abstract_inverted_index.dosage | 101, 116, 171, 188 |
| abstract_inverted_index.events | 147 |
| abstract_inverted_index.forced | 74 |
| abstract_inverted_index.future | 226 |
| abstract_inverted_index.group) | 102 |
| abstract_inverted_index.group. | 189 |
| abstract_inverted_index.groups | 138, 213 |
| abstract_inverted_index.rates, | 218 |
| abstract_inverted_index.safety | 79 |
| abstract_inverted_index.tissue | 26 |
| abstract_inverted_index.total, | 33 |
| abstract_inverted_index.women, | 42 |
| abstract_inverted_index.years; | 40 |
| abstract_inverted_index.adverse | 58, 86, 146, 152 |
| abstract_inverted_index.analyse | 4 |
| abstract_inverted_index.between | 162, 199, 210 |
| abstract_inverted_index.changes | 63, 72, 196 |
| abstract_inverted_index.disease | 27 |
| abstract_inverted_index.dosage, | 66 |
| abstract_inverted_index.events. | 59, 87, 153 |
| abstract_inverted_index.further | 224 |
| abstract_inverted_index.group). | 117 |
| abstract_inverted_index.groups. | 202 |
| abstract_inverted_index.groups; | 165 |
| abstract_inverted_index.improve | 14 |
| abstract_inverted_index.precise | 230 |
| abstract_inverted_index.primary | 49 |
| abstract_inverted_index.provide | 223 |
| abstract_inverted_index.rarely, | 134 |
| abstract_inverted_index.reduced | 11, 113, 170 |
| abstract_inverted_index.safety. | 221 |
| abstract_inverted_index.similar | 149 |
| abstract_inverted_index.started | 91, 109 |
| abstract_inverted_index.studies | 227 |
| abstract_inverted_index.whether | 5 |
| abstract_inverted_index.(reduced | 115 |
| abstract_inverted_index.Eighteen | 88 |
| abstract_inverted_index.Systemic | 118 |
| abstract_inverted_index.assessed | 80 |
| abstract_inverted_index.capacity | 76 |
| abstract_inverted_index.compared | 104 |
| abstract_inverted_index.disease. | 31 |
| abstract_inverted_index.efficacy | 21, 67 |
| abstract_inverted_index.endpoint | 50 |
| abstract_inverted_index.evidence | 206 |
| abstract_inverted_index.followed | 128 |
| abstract_inverted_index.however, | 166 |
| abstract_inverted_index.included | 62 |
| abstract_inverted_index.observed | 158, 194 |
| abstract_inverted_index.patients | 23, 35, 89, 107, 167 |
| abstract_inverted_index.standard | 95, 187 |
| abstract_inverted_index.(standard | 100 |
| abstract_inverted_index.Secondary | 60 |
| abstract_inverted_index.analysed. | 47 |
| abstract_inverted_index.efficacy, | 219 |
| abstract_inverted_index.endpoints | 61 |
| abstract_inverted_index.evaluated | 68 |
| abstract_inverted_index.evidence, | 225 |
| abstract_inverted_index.exhibited | 139 |
| abstract_inverted_index.frequency | 84 |
| abstract_inverted_index.protocols | 232 |
| abstract_inverted_index.sclerosis | 119 |
| abstract_inverted_index.treatment | 8, 16, 92, 110 |
| abstract_inverted_index.arthritis. | 136 |
| abstract_inverted_index.comparable | 140 |
| abstract_inverted_index.connective | 25 |
| abstract_inverted_index.cumulative | 53, 141, 176 |
| abstract_inverted_index.difference | 209 |
| abstract_inverted_index.idiopathic | 130 |
| abstract_inverted_index.initiating | 6 |
| abstract_inverted_index.myopathies | 132 |
| abstract_inverted_index.nintedanib | 7 |
| abstract_inverted_index.rheumatoid | 135 |
| abstract_inverted_index.warranted. | 234 |
| abstract_inverted_index.differences | 156, 192 |
| abstract_inverted_index.frequencies | 150 |
| abstract_inverted_index.maintaining | 20 |
| abstract_inverted_index.maintenance | 160 |
| abstract_inverted_index.significant | 155, 191 |
| abstract_inverted_index.continuation | 17 |
| abstract_inverted_index.inflammatory | 131 |
| abstract_inverted_index.interstitial | 29 |
| abstract_inverted_index.discontinuation | 54, 142, 217 |
| abstract_inverted_index.dose-escalation | 231 |
| abstract_inverted_index.retrospectively | 46 |
| abstract_inverted_index.(CTD)-associated | 28 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 90 |
| corresponding_author_ids | https://openalex.org/A5013618903 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| corresponding_institution_ids | https://openalex.org/I135598925 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.6499999761581421 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.76920321 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |